ubiquinol has been researched along with Malaria* in 1 studies
1 other study(ies) available for ubiquinol and Malaria
| Article | Year |
|---|---|
Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae.
Atovaquone is a new anti-malarial agent that specifically targets the cytochrome bc1 complex and inhibits parasite respiration. A growing number of failures of this drug in the treatment of malaria have been genetically linked to point mutations in the mitochondrial cytochrome b gene. To better understand the molecular basis of atovaquone resistance in malaria, we introduced five of these mutations, including the most prevalent variant found in Plasmodium falciparum (Y268S), into the cytochrome b gene of the budding yeast Saccharomyces cerevisiae and thus obtained cytochrome bc1 complexes resistant to inhibition by atovaquone. By modeling the variations in cytochrome b structure and atovaquone binding with the mutated bc1 complexes, we obtained the first quantitative explanation for the molecular basis of atovaquone resistance in malaria parasites. Topics: Amino Acid Sequence; Animals; Antimalarials; Atovaquone; Cytochromes b; Dose-Response Relationship, Drug; Electron Transport Complex III; Inhibitory Concentration 50; Kinetics; Malaria; Models, Molecular; Molecular Sequence Data; Mutation; Naphthoquinones; Oxygen Consumption; Plasmodium falciparum; Point Mutation; Protein Binding; Saccharomyces cerevisiae; Sequence Homology, Amino Acid; Time Factors; Ubiquinone | 2005 |